AACR: Merck, Kelun’s Anti-TROP2 ADC Shows Early Promise in Gastric Cancer 4/10/2024

TORL Targets Hot ADC Space with Oversubscribed $158M Series B-2 4/10/2024

Birth Control Market Evolves as OTC Opill Hits US Stores 4/10/2024

Can $12 Billion Jumpstart Women’s Health? 4/10/2024

Alphabet Soup: AACR and ACC Dominate Headlines This Week 4/10/2024

YS Biopharma’s Rabies Vaccine Outperforms Commercial Competitor in Phase III Trial 4/10/2024

AACR: Study Suggests Accelerated Approval Doesn’t Always Lead to Clinical Benefit 4/10/2024

7 Billion-Dollar Oncology M&As from Q1 4/10/2024

The IRA Is Already Curtailing Small Molecule Drug Development. Here’s How to Reverse That. 4/10/2024

Poor Customer Data Management Costs Pharma Companies Money: Report 4/10/2024

AACR 2024: What Cancer Researchers Are Talking About 4/10/2024

Novo Inks $600M Deal with Metaphore to Develop Next-Gen Obesity Drugs 5/9/2024

Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024 5/9/2024

Women's Health: Where Politics and Science Meet 5/9/2024

Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies 5/9/2024

Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Finds 5/9/2024

Bespoke Gene Therapy Consortium Targets AAVs for Rare Diseases 5/9/2024

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop 5/9/2024

DEIB Evolves As Criticism, Changing Attitudes Continue 5/9/2024

Dry Promotions: Dealing With a Double-Edged Sword 5/9/2024